Metformin as anticancer agent and adjuvant in cancer combination therapy: Current progress and future prospect
Abstract
Highlights • The inhibitory effect of metformin on cancer can be achieved through insulin-dependent and non-independent mechanisms.• Metformin combines with conventional anticancer therapies such as chemotherapy, radiotherapy, targeted therapy and immunotherapy to fight tumors.• A number of preclinical studies and clinical trials of metformin combination in cancer therapy have been conducted and have results.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.